Wave Life Sciences Ltd. (WVE) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Paul Bolno	President, Chief Executive Officer & Director	1.35M	1974
Gregory L. Verdine	Founder & Director	49,375	1959
Christopher Francis	Senior Vice President of Corporate Development & Head of Emerging Areas	736,936	1978
Chandra Vargeese	Chief Technology Officer	836,605	1961
Kyle Moran	Chief Financial Officer & Principal Accounting Officer	864,681	1971
Erik Ingelsson	Chief Scientific Officer	0	N/A
Kate Rausch	Head of Investor Relations	0	N/A
Sridhar Vaddeboina	Senior Vice President of Chemistry, Manufacturing & Controls	0	N/A
Daryn Lewis	Senior Vice President & Head of Human Resources	0	N/A
Linda Rockett	Senior Vice President & General Counsel	0	N/A

Name

Title

Pay

Year Born

Paul Bolno

President, Chief Executive Officer & Director

1.35M

1974

Gregory L. Verdine

Founder & Director

49,375

1959

Christopher Francis

Senior Vice President of Corporate Development & Head of Emerging Areas

736,936

1978

Chandra Vargeese

Chief Technology Officer

836,605

1961

Kyle Moran

Chief Financial Officer & Principal Accounting Officer

864,681

1971

Erik Ingelsson

Chief Scientific Officer

N/A

Kate Rausch

Head of Investor Relations

N/A

Sridhar Vaddeboina

Senior Vice President of Chemistry, Manufacturing & Controls

N/A

Daryn Lewis

Senior Vice President & Head of Human Resources

N/A

Linda Rockett

Senior Vice President & General Counsel

N/A

Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.